PR Newswire Clinical TrialsOriginal article
Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results
Data ReadoutpositiveBRII-5395Positive
AI Analysis
Summary
Brii Biosciences reported Phase 2b topline data from HBV functional cure studies and announced BRII-5395 mRNA cancer vaccine is entering clinical evaluation for hepatocellular carcinoma. Additional data expected in the second half of 2026.
Clinical Trial Data
Phase
2b
Outcome Details
Phase 2b topline data from HBV functional cure strategy studies reported; additional data expected in 2H 2026
Importance:6/10
Sentiment:
0.60
HBVfunctional curemRNA vaccineHCCPhase 2bclinical developmentcash position
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on August 20, 2026 11:10 PM